Incipiam Pharma ApS: Financial statements 2025
CVR: 44074214
Source: annual report 2025, Danish Business Authority
01/10/2024 – 30/09/2025
Incipiam Pharma ApS (CVR 44074214) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -1,201,246 and a net result of DKK -1,847,358. Equity in the 2025 report amounted to DKK -1,948,853. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,201,246
- Profit/Loss
- DKK -1,847,358
- Equity
- DKK -1,948,853
- Total Assets
- DKK 8,795,384
- Employees
- 1
Official annual report
How creditworthy is Incipiam Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Incipiam Pharma ApS has published its interim report for the period January 1, 2024 to September 30, 2024.
About Incipiam Pharma ApS
Incipiam Pharma ApS is a Danish company of the type Anpartsselskab based in Valby, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Casper Tind Hansen. The company's owners include MTC 2008 HOLDING ApS, CTH Holding Invest ApS and Bondo Hansen Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -1,201,246 and a net result of DKK -1,847,358. Equity in the 2025 report amounted to DKK -1,948,853.